Results 71 to 80 of about 33,952 (165)

Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement. [PDF]

Blood Adv
Xiao A, Zanwar S, Lin Y, Kapoor P, Abdallah N, Buadi FK, Binder M, Dispenzieri A, Dingli D, Gertz MA, Gonsalves W, Hayman SR, Kourelis T, Leung N, Muchtar E, Siddiqui M, Tan M, Warsame R, Rajkumar SV, Kumar S.   +19 more
europepmc   +1 more source

The LVI Component Hypothesis: the lymphatic-to-vascular invasion ratio as an enrichment biomarker for therapy with PD-L1×VEGF-A bispecific antibodies. [PDF]

Front Immunol
Kern KA.
europepmc   +1 more source

The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies. [PDF]

Front Pharmacol
Li Z, Wang X, Shi Q, Guo Y, Dong G, Liu Z.   +5 more
europepmc   +1 more source

Bispecific antibody toxicities

Canadian Medical Association Journal
Britto, Joanne, Mian, Hira, Davies, Gwynivere A., Balitsky, Amaris K.   +3 more
openaire   +2 more sources

Critical Quality Attribute Investigation and Analytical Method Establishment for Glyco-Site-Specific Anti-HER2 Bispecific ADC. [PDF]

Pharmaceuticals (Basel)
Yu X, Wang L, Cao W, Tang Y, Tang T, Fu Y, Yang Y, Yu C, Li Y, Wang L.   +9 more
europepmc   +1 more source

T-Cell Redirecting Antibodies for the Treatment of Multiple Myeloma: Off-the-Shelf T-Cell Immunity. [PDF]

Cancer J
van de Donk NWCJ, Smits F, O'Neill C, Hoekman J, Kruyswijk S, Baglio SR, Zweegman S, Korst CLBM.   +7 more
europepmc   +1 more source

ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window. [PDF]

Mol Cancer Ther
Lee B, Park HJ, Yoo BM, Kim H, Seo A, Hong Y, Lee YS, Yeom D, Son YG, Eom J, Song D, Sung B, Ahn J, Kim J, You WK, Lee SH, Jung J.   +16 more
europepmc   +1 more source

DNA Hypomethylating Agents Preserve T-cell Stemness and Potentiate the Efficacy of CD3-Bispecific Antibodies. [PDF]

Cancer Immunol Res
Aleynick M, Wang Q, Wu JE, Lemus S, Chaimowitz M, Mir H, Warsaw JJ, Guo C, Macdonald LE, Waite JC, Kourtis N, Skokos D.   +11 more
europepmc   +1 more source

Radiotherapy in Combination with CD20×CD3 Bispecific Antibodies for B-Cell Lymphoma: Biological Rationale, Current Evidence, and Open Questions. [PDF]

Cancers (Basel)
Ciammella P, Bavieri A, Nizzoli ME, Alì E.   +3 more
europepmc   +1 more source